Numerous studies have shown that overexpression of, or activating mutations in, PRC2 components, particularly Ezh2, contribute to proliferation and lymphomagenesis in DLBCL patients [40, 41]. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.